Cargando…

The Association between ER, PR, HER2, and ER−/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database

AIMS: The available research on the association between estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), ER−/PR+ status, and the occurrence of lung cancer subsequent to breast cancer in patients (referred to as BC-LuC) had been limited. Consequentl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Hong Yu, Hao, Bao Tan, Gao, Feng Xiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657240/ https://www.ncbi.nlm.nih.gov/pubmed/38021219 http://dx.doi.org/10.1155/2023/7028189

Ejemplares similares

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017)

ODP539 AIPB is a Biomarker for ER+/PR+/Her2- Breast Cancers
por: Cubbedge, Chandler, et al.
Publicado: (2022)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)

Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2− breast cancer: a retrospective cohort study
por: Xie, Yiqun, et al.
Publicado: (2022)

Genetic and clinical landscape of ER + /PR- breast cancer in China
por: Dai, Danian, et al.
Publicado: (2023)

Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
por: Chen, Chih-Jung, et al.
Publicado: (2022)

Adjuvant chemotherapy could benefit early-stage ER/PR positive mucinous breast cancer: A SEER-based analysis
por: Gao, Hong-Fei, et al.
Publicado: (2020)

Association between Acquired Uniparental Disomy and Homozygous Mutations and HER2/ER/PR Status in Breast Cancer
por: Tuna, Musaffe, et al.
Publicado: (2010)

The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes
por: Parise, Carol A., et al.
Publicado: (2015)

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
por: Xu, Junnan, et al.
Publicado: (2018)

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Weight Loss Intervention in Survivors of ER/PR-negative Breast Cancer
por: Vitolins, Mara Z, et al.
Publicado: (2014)

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer
por: Bauer, Katrina, et al.
Publicado: (2010)

Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study
por: Hussein, Israa A, et al.
Publicado: (2020)

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (−) Breast Cancer
por: Du, Feng, et al.
Publicado: (2022)

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance
por: Hu, Xueyang, et al.
Publicado: (2023)

Role of mitochondrial translation in remodeling of energy metabolism in ER/PR(+) breast cancer
por: Koc, Emine C., et al.
Publicado: (2022)

3D Visualization of the Dynamic Bidirectional Talk Between ER/PR and Her2 Pathways
por: Lyv, Jiahong, et al.
Publicado: (2021)

BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma
por: Kumar, Mohit, et al.
Publicado: (2017)

Deep learned tissue “fingerprints” classify breast cancers by ER/PR/Her2 status from H&E images
por: Rawat, Rishi R., et al.
Publicado: (2020)

A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana
por: Seshie, Bernard, et al.
Publicado: (2015)

The Clinical Significance of PR, ER, NF-κB, and TNF-α in Breast Cancer
por: Zhou, Xian-Long, et al.
Publicado: (2014)

ER and PR signaling nodes during mammary gland development
por: Tanos, Tamara, et al.
Publicado: (2012)

Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma
por: Eldien, Marwa Mohammed Serag, et al.
Publicado: (2017)

Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma
por: Andersson, Gustav, et al.
Publicado: (2019)

Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers
por: Parise, Carol A., et al.
Publicado: (2014)

Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling
por: Dai, Xiaofeng, et al.
Publicado: (2014)

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples
por: Wilson, Timothy R., et al.
Publicado: (2014)

An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER(−)/PR(−)/Her2(−) Human Breast Cancer Cells
por: Novikov, Olga, et al.
Publicado: (2016)

Cell-specific regulation of proliferation by Ano1/TMEM16A in breast cancer with different ER, PR, and HER2 status
por: Wu, Huizhe, et al.
Publicado: (2017)

The Diverse Distribution of Risk Factors between Breast Cancer Subtypes of ER, PR and HER2: A 10-Year Retrospective Multi-Center Study in China
por: Song, Qingkun, et al.
Publicado: (2013)

Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium
por: Howat, William J, et al.
Publicado: (2014)

Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast Carcinoma
por: Ahmed, Hussain Gadelkarim, et al.
Publicado: (2011)

Digital Validation of Breast Biomarkers (ER, PR, AR and HER2) in Cytology Specimens Using Three Different Scanners
por: Salama, Abeer M., et al.
Publicado: (2021)

Clinicopathological characteristics and prognostic analysis of breast cancer with a hormone receptor status of ER(-)/PR(+)
por: Wang, Xinli, et al.
Publicado: (2023)

ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer—Reduced CK5 Expression in Metastases
por: Joensuu, Kristiina, et al.
Publicado: (2013)

Pituitary, Gonadal, Thyroid Hormones and Endocrine Disruptors in Pre and Postmenopausal Nigerian Women with ER-, PR- and HER-2-Positive and Negative Breast Cancers
por: Ajayi, Olulope, et al.
Publicado: (2018)

Metformin partially reverses the inhibitory effect of co-culture with ER(-)/PR(-)/HER2(+) breast cancer cells on biomarkers of monocyte antitumor activity
por: Dahmani, Zoheir, et al.
Publicado: (2020)

Establishment and characterization of a new spontaneously immortalized ER(−)/PR(−)/HER2(+) human breast cancer cell line, DHSF-BR16
por: Nobili, Stefania, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_57crll29s0qcv41occ05plfq7f